Note 1. Organization and Summary of Significant Accounting Policies
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] |
Note
1. Organization and Summary of Significant Accounting
Policies
Organization
Oculus
Innovative Sciences, Inc. (the “Company”) was
incorporated under the laws of the State of California in
April 1999 and was reincorporated under the laws of the State
of Delaware in December 2006. The Company’s principal
office is located in Petaluma, California. The Company
develops, manufactures and markets a family of tissue care
products that, based on country specific regulatory
clearances, is designed for a variety of indications ranging
from wound care dressing, irrigation and management to
treating infection and enhancing healing while reducing the
need for antibiotics. The Company’s platform
technology, called Microcyn®, is a proprietary solution
of electrically charged oxychlorine small molecules designed
to treat a wide range of organisms that cause disease
(pathogens).
Basis
of Presentation
The
accompanying unaudited condensed consolidated financial
statements as of December 31, 2011 and for the three and nine
months then ended have been prepared in accordance with the
accounting principles generally accepted in the United States
of America for interim financial information and pursuant to
the instructions to Form 10-Q and Article 8 of Regulation S-X
of the Securities and Exchange Commission (“SEC”)
and on the same basis as the annual audited consolidated
financial statements. The unaudited condensed consolidated
balance sheet as of December 31, 2011, condensed consolidated
statements of operations for the three and nine months ended
December 31, 2011 and 2010, and the condensed consolidated
statements of cash flows for the nine months ended December
31, 2011 and 2010 are unaudited, but include all adjustments,
consisting only of normal recurring adjustments, which the
Company considers necessary for a fair presentation of the
financial position, operating results and cash flows for the
periods presented. The results for the three and nine months
ended December 31, 2011 are not necessarily indicative of
results to be expected for the year ending March 31, 2012 or
for any future interim period. The condensed consolidated
balance sheet at March 31, 2011 has been derived from audited
consolidated financial statements. However, it does not
include all of the information and notes required by
accounting principles generally accepted in the United States
of America for complete consolidated financial statements.
The accompanying condensed consolidated financial statements
should be read in conjunction with the consolidated financial
statements for the year ended March 31, 2011, and notes
thereto included in the Company’s Annual Report on Form
10-K, which was filed with the SEC on June 3, 2011.
Use
of Estimates
The
preparation of condensed consolidated financial statements in
conformity with accounting principles generally accepted in
the United States of America requires management to make
estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosures of contingent
liabilities at the dates of the condensed consolidated
financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could
differ from these estimates. Significant estimates and
assumptions include reserves and write-downs related to
receivables and inventories, the recoverability of long-lived
assets, deferred taxes and related valuation
allowances, valuation of equity and derivative
instruments, and debt discounts. Periodically, the Company
evaluates and adjusts estimates accordingly. The allowance
for uncollectible accounts receivable balances amounted to
$48,000 and $62,000, which are included in accounts
receivable, net in the accompanying December 31, 2011 and
March 31, 2011 condensed consolidated balance sheets,
respectively. The reserve for excess and obsolete inventory
balances amounted to $84,000 and $158,000, which are included
in inventories, net in the accompanying December 31, 2011 and
March 31, 2011 condensed consolidated balance sheets,
respectively.
Net
Loss per Share
The
Company computes basic net loss per share by dividing net
loss per share available to common stockholders by the
weighted average number of common shares outstanding for the
period and excludes the effects of any potentially dilutive
securities. Diluted earnings per share, if presented, would
include the dilution that would occur upon the exercise or
conversion of all potentially dilutive securities into common
stock using the “treasury stock” and/or “if
converted” methods as applicable. The computation of
basic loss per share for the three and nine months ended
December 31, 2011 and 2010 excludes the potentially dilutive
securities summarized in the table below because their
inclusion would be anti-dilutive.
Common
Stock Purchase Warrants and Other Derivative Financial
Instruments
The
Company classifies common stock purchase warrants and other
free standing derivative financial instruments as equity if
the contracts (i) require physical settlement or net-share
settlement or (ii) give the Company a choice of net-cash
settlement or settlement in its own shares (physical
settlement or net-share settlement). The Company classifies
any contracts that (i) require net-cash settlement (including
a requirement to net cash settle the contract if an event
occurs and if that event is outside the control of the
Company), (ii) give the counterparty a choice of net-cash
settlement or settlement in shares (physical settlement or
net-share settlement), or (iii) contain reset provisions as
either an asset or a liability. The Company assesses
classification of its freestanding derivatives at each
reporting date to determine whether a change in
classification between assets and liabilities is required.
The Company determined that its freestanding derivatives,
which principally consist of warrants to purchase common
stock, satisfied the criteria for classification as equity
instruments at December 31, 2011, other than certain warrants
that contain reset provisions that the Company classified as
derivative liabilities as more fully described in Note
5.
Fair
Value of Financial Assets and Liabilities
Financial
instruments, including cash and cash equivalents, accounts
payable and accrued liabilities are carried at cost, which
management believes approximates fair value due to the
short-term nature of these instruments. The fair value of
capital lease obligations and equipment loans approximates
their carrying amounts as a market rate of interest is
attached to their repayment. The Company measures the fair
value of financial assets and liabilities based on the
exchange price that would be received for an asset or paid to
transfer a liability (an exit price) in the principal or most
advantageous market for the asset or liability in an orderly
transaction between market participants on the measurement
date. The Company maximizes the use of observable inputs and
minimizes the use of unobservable inputs when measuring fair
value. The Company uses three levels of inputs that may be
used to measure fair value:
Level
1 — quoted prices in active markets for identical
assets or liabilities
Level
2 — quoted prices for similar assets and liabilities in
active markets or inputs that are observable
Level
3 — inputs that are unobservable (for example cash flow
modeling inputs based on assumptions)
Financial
liabilities measured at fair value on a recurring basis are
summarized below:
Subsequent
Events
Management
has evaluated subsequent events or transactions occurring
through the date the financial statements were issued (Note
11).
Recent
Accounting Pronouncements
In
May 2011, the Financial Accounting Standards Board
(“FASB”) issued Accounting Standards Update
(“ASU”) No. 2011-04, “Fair Value
Measurement (Topic 820) - Amendments to Achieve Common Fair
Value Measurement and Disclosure Requirements in U.S. GAAP
and IFRSs." This ASU addresses fair value measurement and
disclosure requirements within Accounting Standards
Codification (“ASC”) Topic 820 for the purpose of
providing consistency and common meaning between U.S. GAAP
and International Financial Reporting Standards
(“IFRSs”). Generally, this ASU is not intended to
change the application of the requirements in Topic 820.
Rather, this ASU primarily changes the wording to describe
many of the requirements in U.S. GAAP for measuring fair
value or for disclosing information about fair value
measurements. This ASU is effective for periods beginning
after December 15, 2011. It is not expected to have any
impact on the Company’s consolidated financial
statements or disclosures.
In
June 2011, the FASB issued ASU No. 2011-05,
“Comprehensive Income (Topic 220): Presentation of
Comprehensive Income.” This ASU increases the
prominence of other comprehensive income (“OCI”)
in the financial statements and provides companies two
options for presenting OCI, which until now has typically
been placed within the statement of equity. One option allows
an OCI statement to be included with the net income
statement, and together the two will make a statement of
total comprehensive income. Alternately, companies may
present an OCI statement separate from the net income
statement; however, the two statements will have to appear
consecutively within a financial report. This ASU does not
affect the types of items that are reported in OCI, nor does
it affect the calculation or presentation of earnings per
share. For public companies, this ASU is effective for
periods beginning after December 15, 2011. The Company is
evaluating the impact this standard will have on the
Company’s consolidated financial position and results
of operations.
Accounting
standards that have been issued or proposed by the FASB, SEC
and/or other standards-setting bodies that do not require
adoption until a future date are not expected to have a
material impact on the consolidated financial statements upon
adoption.
|